Potential cardioprotective effect of mibefradil in the long-term treatment of hypertension.

Détails

ID Serval
serval:BIB_8495
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Potential cardioprotective effect of mibefradil in the long-term treatment of hypertension.
Périodique
Cardiology
Auteur(s)
Waeber B.
ISSN
0008-6312
Statut éditorial
Publié
Date de publication
1998
Peer-reviewed
Oui
Volume
89
Numéro
Suppl 1
Pages
16-22
Langue
anglais
Notes
Publication types: Journal Article ; Review
Résumé
During the last 2 decades, remarkable progress has been made in the treatment of hypertension with the discovery of new drugs lowering blood pressure by various mechanisms, e.g. calcium channel blockers, angiotensin-converting enzyme inhibitors and angiotensin II antagonists. These antihypertensive agents are now widely used as first-line therapy although there is still no definite proof that they have a cardioprotective effect and reduce the mortality rate in patients with coronary heart disease. Mibefradil is a new calcium antagonist with a novel mechanism of action since it is the only drug available so far able to block T channels. This compound might be particularly effective in preventing cardiac morbidity and mortality. It reduces heart rate when lowering blood pressure, has no negative inotropic effect, allows regression of cardiac hypertrophy and is effective in the treatment of angina. Mibefradil produces a sustained blood pressure reduction with a close to optimal trough:peak ratio. A major advantage of this novel compound is its excellent tolerability over the dose range recommended (50-100 mg/day). In particular, leg edema is seen clearly less often during mibefradil treatment than during therapy with dihydropyridines. Mibefradil has therefore an attractive profile in terms of both efficacy and safety and represents a promising first-line option to treat hypertensive patients.
Mots-clé
Benzimidazoles, Blood Pressure, Calcium Channel Blockers, Calcium Channels, Coronary Disease, Drug Interactions, Follow-Up Studies, Heart Rate, Humans, Hypertension, Mibefradil, Safety, Tetrahydronaphthalenes, Treatment Outcome
Pubmed
Web of science
Création de la notice
19/11/2007 13:46
Dernière modification de la notice
03/03/2018 18:55
Données d'usage